Abbvie (ABBV) is to acquire Immunogen (IMGN). Jenny Horne discusses this Biotech deal as the transaction values IMGN at $10.1B. ABBV is to acquire outstanding shares of IMGN for $31.26 per share in cash. This deal is expected to close in the middle of 2024 and the proposed transaction is expected to be accretive to EPS beginning in 2027. Tune in to find out more about the stock market today.
Market On Close
30 Nov 2023
SHARE
Market On Close
30 Jan 2024
Morning Trade Live
15 Apr 2024
The Watch List
02 Feb 2024
The Watch List
05 Mar 2024
Morning Trade Live
29 Feb 2024
The Watch List
01 Feb 2024